The phase 4 OPTION-VMS real-world study has provided new, critical insights into the management of menopausal symptoms, specifically focusing on the efficacy of fezolinetant (marketed as VEOZAH) in addressing both vasomotor symptoms (VMS) and the debilitating sleep disturbances that often accompany them. Presented at the 2026 International Menopause Society 20th World Congress on Menopause, the preliminary analysis offers a comprehensive look at how this non-hormonal treatment performs outside of highly controlled clinical trial settings, providing a realistic picture of outcomes for women navigating the transition of menopause.
The Clinical Significance of Menopausal Sleep Disturbance
For millions of women, the onset of menopause is marked by more than just the commonly cited hot flashes. Sleep disruption is a primary complaint, with epidemiological data suggesting that between 40% and 60% of women aged 45 to 64 report significant sleep quality degradation during this life stage. The physiological mechanism is complex: hormonal fluctuations, particularly the decline in estrogen, disrupt the body’s thermoregulatory center in the hypothalamus.
This disruption manifests as vasomotor symptoms, or VMS—the clinical term for hot flashes and night sweats. Research indicates that women experiencing moderate to severe VMS are nearly three times more likely to suffer from frequent nighttime awakenings compared to their asymptomatic counterparts. The resulting sleep deprivation contributes to a cascade of secondary health issues, including cognitive fog, mood instability, and a marked reduction in overall quality of life. The OPTION-VMS study sought to quantify the extent to which blocking the neurokinin 3 (NK3) receptor pathway could alleviate these symptoms in real-world clinical practice.
Study Methodology and Data Collection
The OPTION-VMS study is a prospective, observational phase 4 trial designed to capture the real-world experiences of women prescribed non-hormonal therapies for bothersome menopausal symptoms. Unlike traditional phase 3 trials that often rely on strict inclusion criteria, this study prioritizes the diversity of clinical practice, tracking patients as they undergo treatment in standard healthcare settings.
A defining feature of this specific analysis is its dual-pronged approach to data collection. Researchers combined subjective patient-reported outcome measures—where women documented their perceived symptom severity and sleep quality—with objective data derived from wearable actigraphy devices. Actigraphy, a non-invasive method of monitoring physical activity and rest cycles, provides a granular look at sleep architecture that is often missing from self-reported surveys. By integrating these two data sources, the study team created a robust dataset that validates patient experiences with hard, physiological evidence of improved rest.
Key Findings and Chronology of Improvement
The preliminary results highlight a consistent trajectory of improvement for women treated with a 45 mg daily dose of fezolinetant. The primary endpoint of the study focused on the reduction of bothersome VMS at the 12-week mark. The data revealed that participants experienced statistically significant reductions in symptom frequency and severity as early as four weeks into the treatment cycle.
The impact on sleep was equally notable. Participants saw measurable gains in sleep efficiency and continuity at every major milestone measured: weeks 4, 8, and 12. Most significantly, the objective actigraphy data showed a mean reduction of 2.6 nighttime awakenings per night by the conclusion of the 12-week study period. This reduction represents a meaningful change in the sleep hygiene of the participants, potentially allowing for deeper, more restorative REM and deep-sleep cycles.
Mechanism of Action: Targeting the Temperature Center
Fezolinetant represents a departure from traditional hormone replacement therapy (HRT). As a selective neurokinin 3 receptor antagonist, it functions by directly targeting the neurokinin B (NKB) signaling pathway. In the brains of menopausal women, the drop in estrogen levels leads to an imbalance in the kisspeptin/neurokinin/dynorphin (KNDy) neurons, which serve as the body’s thermostat.
By blocking NKB binding, fezolinetant effectively "resets" the thermoregulatory center, preventing the hyper-excitability that triggers hot flashes and night sweats. Because it does not rely on hormonal manipulation, it provides a therapeutic alternative for women who may have contraindications to hormone therapy or who prefer to avoid hormonal interventions.
Expert Perspectives and Clinical Implications
Dr. Marla Shapiro, representing the Department of Family and Community Medicine at the University of Toronto and serving as the lead author of the presentation, underscored the significance of these findings during the congress. "Hot flashes and night sweats can have a far-reaching impact on women’s daily lives, including their sleep, quality of life and overall well-being," she stated. She emphasized that the OPTION-VMS data provides clinicians with a higher level of confidence when discussing treatment options, as the evidence now includes both clinical trial data and real-world performance metrics.
From the manufacturer’s perspective, the focus remains on the patient experience. Shayna Mancuso, DO, FACOG, executive medical director and head of US medical affairs for women’s health at Astellas, noted that the study’s design serves to bridge the gap between academic research and the day-to-day realities of patient care. "By evaluating women’s experiences in routine clinical practice, we are building a deeper understanding of the outcomes that matter most to women and their clinicians," Mancuso said.
Safety Profile and Regulatory Context
A vital component of any phase 4 study is the continued monitoring of safety signals in a broader population. The OPTION-VMS analysis reported no new or unexpected safety concerns regarding fezolinetant. Hepatic laboratory findings, which are often monitored in clinical trials for new classes of medications, were described as mild and infrequent. Crucially, the study reported that none of the observed laboratory findings necessitated a discontinuation of the treatment or withdrawal from the study, suggesting a favorable benefit-risk profile for the patient population evaluated.
Broader Impact on Menopause Care
The implications of these findings for the medical community are significant. For years, the treatment of menopausal symptoms was limited to a relatively small toolkit, dominated by HRT. The introduction of NK3 receptor antagonists has provided a new mechanism of action, and the OPTION-VMS study confirms that the efficacy observed in controlled settings translates effectively into the real world.
Furthermore, the emphasis on sleep as a primary outcome measure reflects a changing priority in medical research. Physicians are increasingly recognizing that addressing VMS is not just about comfort; it is about addressing the secondary health risks associated with chronic sleep deprivation, such as cardiovascular strain and impaired mental health. By improving sleep architecture, therapies like fezolinetant may have systemic health benefits that extend well beyond the reduction of hot flashes.
As healthcare providers continue to incorporate these findings into their practice, the focus will likely shift toward personalized medicine, where the specific symptom profile of the patient—including the severity of their sleep disruption—dictates the therapeutic approach. The 2026 World Congress on Menopause has provided a platform for these discussions, highlighting a future where the menopausal transition is treated with precision and evidence-based interventions that prioritize both systemic health and daily quality of life.
Future Directions
While these preliminary findings are encouraging, the scientific community expects further analysis from the OPTION-VMS cohort. Long-term durability of the sleep improvements and the potential for dose-dependent responses in different demographic groups remain key areas of interest. Additionally, the integration of wearable technology into clinical research sets a new standard for how pharmaceutical companies and researchers track the effectiveness of treatments for chronic, quality-of-life-impacting conditions. As more data is collected, the medical community will be better equipped to provide tailored, non-hormonal solutions that address the multifaceted challenges of the menopausal transition.
